The CGRP peptide exerts its influence by binding to a CGRP receptor and activating intracellular signalling pathways, such as the cAMP (cyclic adenosine monophosphate) pathway.1 By interacting with second-order neurons passing on a nociceptive signal, interacting with smooth muscle cells lining the cerebral artery, and interacting with inflammatory mediators such as mast cells, there are several potential points of intervention where anti-CGRP therapies might arrest migraine pathology.1,2
Read more about targeted therapies in migraine, such as triptans and CGRP medications
Related content
Migraine is a prevalent neurological disorder characterized by recurrent and disabling attacks of moderate to severe headache
Migraine affects an estimated 1.1 billions worldwide and ranks as the 2nd leading cause of disability, while being the leading among young adults.
In human models of migraine, a suspected pharmacological migraine trigger is administered either orally or via infusion to a participant with migraine or a healthy volunteer, typically within a double-blinded, randomized, placebo-controlled design